JP2022550664A5 - - Google Patents

Info

Publication number
JP2022550664A5
JP2022550664A5 JP2022508963A JP2022508963A JP2022550664A5 JP 2022550664 A5 JP2022550664 A5 JP 2022550664A5 JP 2022508963 A JP2022508963 A JP 2022508963A JP 2022508963 A JP2022508963 A JP 2022508963A JP 2022550664 A5 JP2022550664 A5 JP 2022550664A5
Authority
JP
Japan
Prior art keywords
dry powder
pharmaceutical composition
powder pharmaceutical
weight
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550664A (ja
JP7678793B2 (ja
Filing date
Publication date
Priority claimed from GBGB1911517.9A external-priority patent/GB201911517D0/en
Application filed filed Critical
Publication of JP2022550664A publication Critical patent/JP2022550664A/ja
Publication of JP2022550664A5 publication Critical patent/JP2022550664A5/ja
Application granted granted Critical
Publication of JP7678793B2 publication Critical patent/JP7678793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508963A 2019-08-12 2020-08-12 エンシフェントリンを含む医薬組成物 Active JP7678793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1911517.9A GB201911517D0 (en) 2019-08-12 2019-08-12 Pharmaceutical composition
GB1911517.9 2019-08-12
PCT/GB2020/051914 WO2021028679A1 (en) 2019-08-12 2020-08-12 Pharmaeutical composition comprising ensifentrine

Publications (3)

Publication Number Publication Date
JP2022550664A JP2022550664A (ja) 2022-12-05
JP2022550664A5 true JP2022550664A5 (https=) 2023-08-08
JP7678793B2 JP7678793B2 (ja) 2025-05-16

Family

ID=67991071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508963A Active JP7678793B2 (ja) 2019-08-12 2020-08-12 エンシフェントリンを含む医薬組成物

Country Status (15)

Country Link
US (1) US20220265549A1 (https=)
EP (1) EP4013384A1 (https=)
JP (1) JP7678793B2 (https=)
KR (1) KR20220045214A (https=)
CN (1) CN114286672A (https=)
AU (1) AU2020328223B2 (https=)
BR (1) BR112022002630A2 (https=)
CA (1) CA3144713A1 (https=)
GB (1) GB201911517D0 (https=)
IL (2) IL326396A (https=)
MX (1) MX2022001724A (https=)
MY (1) MY208922A (https=)
PH (1) PH12022550322A1 (https=)
WO (1) WO2021028679A1 (https=)
ZA (1) ZA202201322B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307855B2 (ja) * 2019-10-11 2023-07-12 テレフオンアクチーボラゲット エルエム エリクソン（パブル） 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN120787157A (zh) * 2022-10-20 2025-10-14 维罗纳制药公司 使用恩塞芬汀治疗特发性肺纤维化
KR20250087621A (ko) * 2022-10-28 2025-06-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
AU2024309346C1 (en) 2023-06-26 2026-03-12 Verona Pharma Plc Particulate composition comprising ensifentrine
WO2025052119A1 (en) * 2023-09-06 2025-03-13 Verona Pharma Plc Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE60005493T2 (de) 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP2968312B1 (en) * 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
MY196072A (en) 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Similar Documents

Publication Publication Date Title
JP2022550664A5 (https=)
JP2022513566A5 (https=)
HRP20211035T1 (hr) Tekuća formulacija za inhalaciju koja sadrži rpl554
Yang et al. Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery
JP2013540123A5 (https=)
JP7678793B2 (ja) エンシフェントリンを含む医薬組成物
JP2017528479A5 (https=)
JP2002537249A (ja) 喘息のためのホルモテロールおよびプロピオン酸フルチカゾンの組み合わせ
JP2007520508A5 (https=)
JP2021522161A5 (https=)
JP2013529606A (ja) 抗ムスカリン薬含有乾燥粉末配合物
JP2019534270A5 (https=)
TW201206499A (en) Dry powder inhalation composition
JP2023071886A5 (https=)
AU2005316687B2 (en) Compositions and methods for pulmonary conditions
JP2009515941A (ja) 医薬組成物
HUP0303755A2 (hu) Szalmeterol és flutikaszon-propionát kombináció alkalmazása és ezt tartalmazó gyógyszerkészítmény
JP2022526367A5 (https=)
KR102637303B1 (ko) 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
JP2008502699A5 (https=)
RU2022103508A (ru) Фармацевтическая композиция, содержащая энсифентрин
AU2018392458A1 (en) Surfactant formulations for inhalation
AU2018392461B2 (en) Surfactant formulations for inhalation
KR102637298B1 (ko) 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
RU2021109697A (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции